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Summary Introduction: The recent outbreak of severe acute respiratory syndrome
(SARS) warrants the search for effective antiviral agents to treat the disease. This
study describes the assessment of the antiviral potential of nitric oxide (NO) against
SARS coronavirus (SARS-CoV) strain Frankfurt-1 replicating in African Green Monkey
(Vero E6) cells.
Results: Two organic NO donor compounds, S-nitroso-N-acetylpenicillamine (SNAP)
and sodium nitroprusside (SNP), were tested in a broad range of concentrations. The
non-nitrosylated form of SNAP, N-acetylpenicillamine (NAP), was included as a con-
trol compound in the assay. Antiviral activity was estimated by the inhibition of the
SARS-CoV cytopathic effect in Vero E6 cells, determined by a tetrazolium-based col-
orimetric method. Cytotoxicity of the compounds was tested in parallel.
Conclusion: The survival rate of SARS-CoV infected cells was greatly increased by
the treatment with SNAP, and the concentration of this compound needed to in-
hibit the viral cytopathic effect to 50% was 222M, with a selectivity index of 3.
No anti-SARS-CoV effect could be detected for SNP and NAP.
© 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Introduction
Severe acute respiratory syndrome (SARS) has re-
cently emerged as a new severe human disease, re-
sulting globally in 774 deaths from 8098 reported
probable cases (as of the 26th of September 2003).
A novel member of the Coronaviridae family has
been identiﬁed as the causative agent of this pul-
monary disease.1 Thus far, treatment of SARS cases
has been largely empirical and has usually included
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an antiviral agent such as ribavirin or a combination
of lopinavir/ritonavir and steroids. It is however un-
clear whether any of these treatments were able to
alter the ultimate outcome of the disease.2,3
During the SARS epidemic, Chen and colleagues
included inhalation of NO gas in the treatment of
a number of SARS patients. Medicinal NO gas, a
gaseous blend of nitric oxide (0.8%) and nitrogen
(99.2%), was given for three days or longer, initially
at 30 ppm and then at 20 and 10 ppm on the sec-
ond and third day (unpublished data). Their ﬁnd-
ings suggest not only an immediate improvement of
oxygenation but also a lasting effect on the disease
itself after termination of inhalation of NO.
NO is a key molecule in the pathogenesis of
infectious diseases. In a variety of microbial infec-
tions, NO biosynthesis occurs through the expres-
sion of an inducible nitric oxide synthase (iNOS).
This molecule has been reported to have antiviral
effects against a variety of DNA and RNA viruses,
including mouse hepatitis virus (MHV), a murine
coronavirus.4 In a recent study, replication of two
SARS-CoV isolates (FFM-1 and FFM-2) was shown
to be greatly inhibited by glycyrrhizin, an active
compound of liquorice roots.5 Glycyrrhizin upregu-
lates the expression of iNOS and production of NO
in macrophages.6
Although the initial global outbreak of SARS ap-
pears to have been successfully contained, SARSwill
remain a serious concern while there continues to
be no suitable vaccine or effective drug treatment.
Materials and methods
In this study we examined the antiviral activ-
ity of nitric oxide (NO) against SARS coronavirus
(SARS-CoV) isolate Frankfurt-1 (FFM-1). Two NO
donor compounds, S-nitroso-N-acetylpenicillamine
(SNAP, Sigma, Belgium) and sodium nitroprusside
(SNP, Sigma, Belgium), were added to conﬂuent
African Green monkey (Vero E6) cells. SNAP re-
leases NO in aqueous solutions with a half-life of
approximately 4 hours.7 The non-nitrosylated form
of SNAP, N-acetylpenicillamine (NAP, Sigma, Bel-
gium) was included as a control compound in the
assay. Antiviral activity and cytotoxicity measure-
ments were based on the viability of cells that had
been infected or not infected with 100 CCID50 (50%
cell culture infective doses) of the SARS-CoV in the
presence of various concentrations of the test com-
pounds. Three days after infection, the number of
viable cells was quantiﬁed by a tetrazolium-based
colorimetric method, in which the reduction
of the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) dye (CellTiter 96 AQueous One Solution kit,
Promega, The Netherlands) by cellular dehydro-
genases to an insoluble coloured formazan was
measured in a spectrophotometer (Multiskan EX,
Thermo Labsystems, Belgium) at 492 nm.8,9 The
selectivity index was determined as the ratio of
the concentration of the compound that reduced
cell viability to 50% (CC50 or 50% cytotoxic con-
centration) to the concentration of the compound
needed to inhibit the viral cytopathic effect to
50% of the control value (IC50 or 50% inhibitory
concentration).
The amount of NO produced by SNAP in cul-
ture medium was determined by assaying its
stable end-product, NO2− (nitrite) in a cell cul-
ture environment. Freeze-thawed cell culture
samples were centrifuged at 300 g for 10min;
equal volumes (100l) of the sample supernatants
and Griess reagent (1% sulphanilamide, 0.1%
N-1-naphthylethylenediamine, 5% H3PO4) (Sigma,
Belgium) were mixed and incubated for 10min at
37 ◦C. The optical density at 540 nm was measured
with an automated multiscan spectrophotometer. A
range of sodium nitrite dilutions served to generate
a standard curve for each assay.
Results and discussion
SNAP inhibited SARS-CoV replication at non-toxic
concentrations (222M) with a selectivity index of
2.6 (Table 1). The NO concentration released by
222M SNAP is between 30—55M NO.
Table 1 Activity of compounds against SARS-corona-
virus in Vero E6 cell culture.
Compound IC50a
(M)
CC50a
(M)
Selectivity
index
S-nitroso-N-
acetylpeni-
cillamine
(SNAP)
222.3 ±
83.7
587.7 ±
22.5
2.6
N-acetylpeni-
cillamine
(NAP)
>500 >500 NC
Sodium
nitroprusside
(SNP)
>221.3 221.3 ±
40.5
NC
N-nitro-
L-arginine
methyl ester
>500 >500 NC
IC50: inhibitory concentration of compound. CC50:
cytotoxic concentration. NC: not calculatable.
a Mean of ﬁve assays ±SD.
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Figure 1 (A) Increased survival rate of SARS FFM-1 infected Vero E6 cells by the treatment of SNAP. Optical
density at 492 nm of mitochondrial activity was measured. Data are expressed as means± S.D. (B) Percent pro-
tection achieved by the compounds in SARS-CoV infected cells is calculated as follows: 100 × [(ODvirus+ compound −
ODsvirus control)/(ODcell control− ODsvirus control)]/(ODcompound control/ODcell control). Bars indicate SD.
No protective effect below the CC50 could be
demonstrated for SNP. The difference in activity
between these two NO donor compounds might be
explained by a different mechanism of releasing
NO. SNAP is a direct donor of NO and generates
NO in aqueous solutions through hydrolysis, while
SNP only releases NO after reaction with a reducing
agent.10—12
No protective effect could be obtained with
N-acetylpenicillamine (NAP), which is the non-nitro-
sylated form of SNAP and does not release NO in
solution (Figure 1). These results illustrate that
the protective effect of SNAP is a consequence of
NO release and not of a potential solitary antiviral
effect of the N-acetyl-penicillamine moiety.
In this study, we provide additional evidence
that NO and NO-donors may have an antiviral ef-
fect against the SARS-CoV and we speculate that
the prolonged effect of inhalation of NO gas ob-
served earlier could be an antiviral effect of NO
against SARS-CoV. Based on our results we en-
courage the inclusion of inhalation of NO in the
treatment of SARS. NO-donors, including SNAP,
have been described as potential therapeutics
in the treatment of cardiovascular disease.13 To
conﬁrm the anti-SARS-CoV effect of NO gas and
NO donors and before SNAP can be used in SARS
treatment, additional in vivo experiments are
required.
As resurgence of the SARS outbreak is a dis-
tinct possibility, the search for antivirals effective
against the SARS-CoV remains an important en-
deavour.
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